Boehringer Ingelheim Limited
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$705,714
Doctors Paid
14
Transactions
1,446
2021 Total
$74,306
Payment Breakdown by Category
Consulting$484,865 (68.7%)
Research$220,849 (31.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $484,865 | 78 | 68.7% |
| Unspecified | $220,849 | 1,368 | 31.3% |
Payments by Type
General
$484,865
78 transactions
Research
$220,849
1,368 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| EASE-2 (52w eff/safety) T1DM pat | $79,497 | 0 | 429 |
| BI 685509 Dose finding/PoCC in Non-Diabetic CKD | $66,553 | 0 | 81 |
| Nintedanib in PF-ILD (extension) | $46,283 | 0 | 379 |
| BI 905677 phase I first-in-man dose finding study | $11,797 | 0 | 15 |
| RE-DUAL PCI | $11,208 | 0 | 333 |
| Ph Ib/II BI836845 + enzalutamide CRPC | $2,874 | 0 | 129 |
| Phase I BI907828 in advanced TP53WT/MDM2-amplified tumors | $2,637 | 0 | 2 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Internal Medicine | $203,200 | 4 | $50,800 |
| Cardiovascular Disease | $184,842 | 4 | $46,211 |
| Endocrinology, Diabetes & Metabolism | $92,013 | 3 | $30,671 |
| Neurology | $4,810 | 3 | $1,603 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Dr. James Januzzi, Md, MD | Internal Medicine | Boston, MA | $97,575 | $0 |
| Christopher Cannon, Md, MD | Cardiovascular Disease | Boston, MA | $97,117 | $0 |
| Andrew Vantosh, Md, MD | Cardiovascular Disease | Roslyn, NY | $75,875 | $0 |
| Daniel Kolansky, Md, MD | Internal Medicine | Philadelphia, PA | $65,350 | $0 |
| Dr. S. Sethu Reddy, Md, Mba, MD, MBA | Endocrinology, Diabetes & Metabolism | Mt Pleasant, MI | $47,762 | $0 |
| Dr. Joseph Garasic, Md, MD | Internal Medicine | Boston, MA | $39,525 | $0 |
| Marwan Hamaty, Md, MD | Endocrinology, Diabetes & Metabolism | Cleveland, OH | $26,299 | $0 |
| Priyathama Vellanki, M.d, M.D | Endocrinology, Diabetes & Metabolism | Atlanta, GA | $17,952 | $0 |
| Dr. Deepak Bhatt, Md, MD | Cardiovascular Disease | New York, NY | $6,650 | $0 |
| Erik Ohman, Mb, Bch, MB, BCH | Cardiovascular Disease | Durham, NC | $5,200 | $0 |
| Karen Hirsch, Md, MD | Neurology | Stanford, CA | $4,185 | $0 |
| Dr. Malissa Wood, Md, MD | Internal Medicine | Fort Myers, FL | $750.00 | $0 |
| Carlos Kase, M.d, M.D | Neurology | Boston, MA | $375.00 | $0 |
| Dr. Tanya Turan, M.d, M.D | Neurology | Charleston, SC | $250.00 | $0 |
Ad
Top Products
- PRADAXA $297,372
- JARDIANCE $171,359
Payment Categories
- Consulting $484,865
- Research $220,849
About Boehringer Ingelheim Limited
Boehringer Ingelheim Limited has made $705,714 in payments to 14 healthcare providers, recorded across 1,446 transactions in the CMS Open Payments database. In 2021, the company paid $74,306. The top product by payment volume is PRADAXA ($297,372).
Payments were distributed across 4 medical specialties. The top specialty by payment amount is Internal Medicine ($203,200 to 4 doctors).
Payment categories include: Consulting ($484,865), Research ($220,849).